Bicara gains buy rating as BofA sees SoC potential in cancer drug Ficera

Bank of America has initiated coverage of Bicara Therapeutics (NASDAQ:BCAX) with a “Buy” rating and a $35 price objective, citing the potential of its lead drug candidate to reshape first-line treatment for a form of head and neck cancer, according to a research note published Tuesday. The analysts pointed to the company's lead asset ficerafusp alfa (ficera) as the central driver of their outlook.